1. Home
  2. ATHA vs CODX Comparison

ATHA vs CODX Comparison

Compare ATHA & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • CODX
  • Stock Information
  • Founded
  • ATHA 2011
  • CODX 2013
  • Country
  • ATHA United States
  • CODX United States
  • Employees
  • ATHA N/A
  • CODX N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • CODX Medical/Dental Instruments
  • Sector
  • ATHA Health Care
  • CODX Health Care
  • Exchange
  • ATHA Nasdaq
  • CODX Nasdaq
  • Market Cap
  • ATHA 18.2M
  • CODX 15.6M
  • IPO Year
  • ATHA 2020
  • CODX 2017
  • Fundamental
  • Price
  • ATHA $4.72
  • CODX $0.38
  • Analyst Decision
  • ATHA
  • CODX Strong Buy
  • Analyst Count
  • ATHA 0
  • CODX 3
  • Target Price
  • ATHA N/A
  • CODX $2.25
  • AVG Volume (30 Days)
  • ATHA 25.6K
  • CODX 3.1M
  • Earning Date
  • ATHA 11-06-2025
  • CODX 11-13-2025
  • Dividend Yield
  • ATHA N/A
  • CODX N/A
  • EPS Growth
  • ATHA N/A
  • CODX N/A
  • EPS
  • ATHA N/A
  • CODX N/A
  • Revenue
  • ATHA N/A
  • CODX $507,892.00
  • Revenue This Year
  • ATHA N/A
  • CODX N/A
  • Revenue Next Year
  • ATHA N/A
  • CODX $31.58
  • P/E Ratio
  • ATHA N/A
  • CODX N/A
  • Revenue Growth
  • ATHA N/A
  • CODX N/A
  • 52 Week Low
  • ATHA $2.20
  • CODX $0.23
  • 52 Week High
  • ATHA $6.79
  • CODX $1.55
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 61.31
  • CODX 49.84
  • Support Level
  • ATHA $4.31
  • CODX $0.32
  • Resistance Level
  • ATHA $4.95
  • CODX $0.38
  • Average True Range (ATR)
  • ATHA 0.37
  • CODX 0.04
  • MACD
  • ATHA -0.04
  • CODX -0.00
  • Stochastic Oscillator
  • ATHA 73.60
  • CODX 58.04

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

About CODX Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Share on Social Networks: